Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors
文摘
Purpose LY2181308 is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue. This phase I dose escalation study evaluated the tolerability, pharmacokinetics, and anticancer activity of LY2181308 in Japanese.